Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

49.69 +0.61 (+1.24%)

Streaming Delayed Price Updated: 1:13 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

82 83 Next >

Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms

November 19, 2024

From Bristol Myers Squibb

Via Business Wire

Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases ↗

November 18, 2024

Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.

Via Benzinga

Not-So-Big Pharma ↗

November 16, 2024

Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration.

Via Talk Markets

Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 16 ↗

November 16, 2024

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Nov. 11-15, 2024.

Via Talk Markets

Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue ↗

November 15, 2024

Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent value rights holders' payments.

Via Benzinga

Topics Lawsuit

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

November 15, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors

November 15, 2024

From Bristol Myers Squibb

Via Business Wire

Want Decades of Passive Income? Buy This Index Fund and Hold It Forever ↗

November 15, 2024

This fund could be the perfect investment for those wanting financial freedom through endlessly growing dividends.

Via The Motley Fool

2 Beaten-Down Dividend Stocks to Buy and Hold ↗

November 14, 2024

They're down, but they aren't out, at least not in the eyes of patient investors.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 13, 2024

Via Benzinga

Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default ↗

November 13, 2024

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, impacting future trial plans.

Via Benzinga

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News ↗

November 13, 2024

The company is now pivoting its technology to the cardiovascular space under a partnership with Bristol Myers Squibb.

Via Investor's Business Daily

3 Stocks Seeing Insider Buys: CNC, PFE, BMY ↗

November 12, 2024

Investors closely monitor insider buys, as they can give hints surrounding the long-term picture. Let’s take a closer look at the transactions for those interested in trading like the insiders.

Via Talk Markets

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio ↗

November 12, 2024

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy.

Via Benzinga

This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

November 12, 2024

Via Benzinga

Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock ↗

November 12, 2024

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, predicting significant stock outperformance.

Via Benzinga

What's Going On With Bristol-Myers Squibb Shares Monday? ↗

November 11, 2024

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie Inc (NYSE:ABBV) announced that its Phase 2 EMPOWER trials did not meet...

Via Benzinga

Dow, S&P 500 On Track For Milestone Closes ↗

November 11, 2024

Wall Street is extending its post-election rally into a new week.

Via Talk Markets

Topics Stocks

AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated ↗

November 11, 2024

AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company's broader drug pipeline.

Via Benzinga

Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal ↗

November 11, 2024

Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the company.

Via Benzinga

AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges ↗

November 11, 2024

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for next steps.

Via Benzinga

MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday ↗

November 11, 2024

Via Benzinga

Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails ↗

November 11, 2024

AbbVie stock also tumbled after its experimental schizophrenia treatment failed in two Phase 2 studies.

Via Investor's Business Daily

Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024

November 11, 2024

From Bristol Myers Squibb

Via Business Wire

MarketBeat Week in Review – 11/4 - 11/8

November 09, 2024

Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts

Via MarketBeat

Topics Economy Government

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks ↗

November 08, 2024

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and...

Via Benzinga

Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast ↗

November 06, 2024

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the consensus of $4.12 billion.

Via Benzinga

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

November 05, 2024

From Bristol Myers Squibb

Via Business Wire

Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings

November 05, 2024

After strong earnings reports, Merck may be a better choice than Bristol-Meyers in the short term - but both may present a challenge for buy-and-hold investors.

Via MarketBeat

Topics Intellectual Property

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo ↗

November 04, 2024

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results.

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

82 83 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.